Following the impressive progress in the treatment of relapsing–remitting multiple sclerosis
(MS), the major challenge ahead is the development of treatments to prevent or delay the …

Therapies for infiltrative inflammation in multiple sclerosis (MS) have advanced greatly, but
neurodegeneration and compartmentalized inflammation remain virtually untargeted as in …

The inability of the mammalian central nervous system (CNS) to undergo spontaneous
regeneration has long been regarded as a central tenet of neurobiology. However, while this …

Objective: Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative
disease that is not easily detectable in the early stage. This study proposed an efficient …

Introduction Conventional imaging measures remain a key clinical tool for the diagnosis
multiple sclerosis (MS) and monitoring of patients. However, most measures used in the …

One of the hallmarks of Alzheimer's disease (AD) is the deposition of amyloid plaques in the
brain parenchyma, which occurs 7–15 years before the onset of cognitive symptoms of the …

Abstract Background Annualized Relapse Rate (ARR) is one of the most important
indicators of disease progression in patients with Multiple Sclerosis (MS). However, imaging …

Background Amyloid positron emission tomography (PET) can measure in-vivo
demyelination in patients with multiple sclerosis (MS). However, the value of 18 F-labeled …

Progressive multiple sclerosis poses a considerable challenge in the evaluation of disease
progression and treatment response owing to its multifaceted pathophysiology. Traditional …

INTRODUCTION The Centiloid scale aims to harmonize amyloid beta (Aβ) positron
emission tomography (PET) measures across different analysis methods. As Centiloids were …